BioCentury
ARTICLE | Clinical News

Gaboxadol: Ph II STARS started

February 10, 2017 9:19 PM UTC

Ovid began the double-blind, placebo-controlled, U.S. Phase II STARS trial to evaluate once- and twice-daily oral gaboxadol in about 75 patients. Ovid has exclusive, worldwide rights to gaboxadol from...